CERS
Cerus Corporation · NASDAQ
- Market cap
- $374.7M
Cerus Corporation (CERS) is a Medical/Dental Instruments company listed on NASDAQ. In the last 30 days Quantisnow tracked 8 wire items for CERS, including 3 earnings updates, 3 SEC filings and 1 press release or news item. The most recent was published Nov 13, 2026.
CERS rankings
Financial highlights
Full financials- Revenue, TTM
- $254.23M
- Net income, TTM
- -$7.36M
- Net margin
- -2.9%
- Free cash flow, TTM
- $494.0K
- Cash
- $16.35M
For the twelve months ended Sep 30, 2026, from SEC filings. Not investment advice.
News · 26 weeks35+250%
2026-05-242026-11-15
Mix990d
- Earnings3(33%)
- SEC Filings3(33%)
- Other2(22%)
- 13D/G1(11%)
Activity · 52 weeks8039 active days
Tap a day to see what happenedEarningsInsiderAnalystFilings and news
Latest news
25 items- 13D/GAmendment: SEC Form SCHEDULE 13G/A filed by Cerus CorporationSCHEDULE 13G/A - CERUS CORP (0001020214) (Subject)
- PRCerus Corporation to Participate in the 17th Annual Craig-Hallum Alpha Select ConferenceCerus Corporation (NASDAQ:CERS) announced today that members of the Company’s management will participate in and host one-on-one investor meetings at the 17th Annual Craig-Hallum Alpha Select Conference taking place in New York City on Tuesday, November 17. ABOUT CERUS Cerus Corporation is dedicated solely to safeguarding the world’s blood supply and aims to become the preeminent global blood products company. Headquartered in Concord, California, the company develops and supplies vital technologies and pathogen-protected blood components to blood centers, hospitals, and ultimately patients who rely on safe blood. The INTERCEPT Blood System for platelets and plasma is available globally
- SECSEC Form S-3 filed by Cerus CorporationS-3 - CERUS CORP (0001020214) (Filer)
- SECSEC Form 10-Q filed by Cerus Corporation10-Q - CERUS CORP (0001020214) (Filer)
- SECCerus Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - CERUS CORP (0001020214) (Filer)
- PRCerus Corporation Announces Third Quarter 2026 Financial ResultsThird quarter 2026 total revenue of $64.0 million; third quarter 2026 product revenue of $57.7 million, +10% Y/Y Announced positive topline Phase 3 RedeS results of the INTERCEPT Blood System for red blood cells (RBCs) Cerus Corporation (NASDAQ:CERS) announced today financial results for the third quarter ended September 30, 2026, and provided a business update. "Our solid performance in Q3 builds upon a strong first half of 2026 and increases our confidence as we approach year-end," said Vivek Jayaraman, Cerus’s president and chief executive officer. "Continued growth from our IFC business, core platelet franchise and international INT 200 rollout strengthens our foundation as we wor
- PRCerus Corporation Announces Positive Topline Results from Phase 3 RedeS Trial of the INTERCEPT Blood System for Red Blood CellsMet primary efficacy endpoint demonstrating non-inferiority of INTERCEPT Red Blood Cells (RBCs) to conventional RBCs by adjusted hemoglobin increment Primary safety endpoints: No statistically significant difference in related treatment-emergent adverse events (TEAEs) between treatment and control arms No evidence of hemolysis or clinical impact detected in treatment-emergent, low titer, transient antibodies, which were observed in RedeS, consistent with Cerus’ prior ReCePI study Cerus Corporation (NASDAQ:CERS) today announced positive topline results from the Phase 3 RedeS (NCT03037164) trial. "Over the past decade, pathogen reduction technology has become an integral compo
- PRCerus Corporation to Release Third Quarter 2026 Financial Results on November 2, 2026Cerus Corporation (NASDAQ:CERS) announced today that its third quarter 2026 financial results will be released on Monday, November 2, 2026, after the close of the stock market. The Company will host a conference call and webcast at 4:30 P.M. ET, during which management will discuss the Company’s financial results and provide a general business overview and outlook. To listen to the live webcast and view the presentation slides, please visit the Investor Relations page of the Cerus website at http://ir.cerus.com. Participants may register for the call here. While not required, interested participants are encouraged to join 10 minutes prior to the start of the event. A replay will be avai
- PRCerus Corporation Announces Workshop and Abstracts at the 2026 AABB Annual MeetingCerus Corporation (NASDAQ:CERS) announced today that it will host an industry workshop on the implementation and real-world experience with INTERCEPT Platelets and INTERCEPT Fibrinogen Complex, or IFC*, at the 2026 Association for the Advancement of Blood and Biotherapies (AABB) Annual Meeting, taking place in Atlanta, Georgia from October 17 through October 19. The AABB Annual Meeting attracts healthcare professionals, scientists, and other experts from around the globe involved in transfusion medicine and biotherapies. "We are pleased to highlight IFC at the 2026 AABB Annual Meeting, including an industry workshop focused on real-world experiences," said Vivek Jayaraman, Cerus’ presiden
- INSIDERChief Legal Officer Jensen Chrystal sold $89,529 worth of shares (30,000 units at $2.98) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 936,657 units (SEC Form 4)4 - CERUS CORP (0001020214) (Issuer)
- SECSEC Form S-8 filed by Cerus CorporationS-8 - CERUS CORP (0001020214) (Filer)
- SECSEC Form 10-Q filed by Cerus Corporation10-Q - CERUS CORP (0001020214) (Filer)
- SECCerus Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - CERUS CORP (0001020214) (Filer)
- PRCerus Corporation Announces Second Quarter 2026 Financial ResultsSecond Quarter 2026 Total Revenue of $63.3 million; Second Quarter 2026 Product Revenue of $57.4 million, +10% Y/Y Raising Lower End of 2026 Product Revenue Guidance: Range now $229 to $231 million; Raising 2026 IFC Sales Outlook to $23 to $25 million, up approximately 40% to 50% Y/Y Cerus Corporation (NASDAQ:CERS) announced today financial results for the second quarter ended June 30, 2026, and provided a business update. "This quarter we made significant progress in expanding patient access to safer blood components around the globe," said Vivek Jayaraman, Cerus’ president and chief executive officer. "I’m particularly pleased with the performance of our INTERCEPT Fibrinogen Complex
- INSIDERChief Executive Officer Jayaraman Vivek K sold $52,665 worth of shares (16,666 units at $3.16) as part of a pre-agreed trading plan, decreasing direct ownership by 0.74% to 2,232,211 units (SEC Form 4)4 - CERUS CORP (0001020214) (Issuer)
- PRCerus Corporation to Release Second Quarter 2026 Financial Results on July 30, 2026Cerus Corporation (NASDAQ:CERS) announced today that its second quarter 2026 financial results will be released on Thursday, July 30, 2026, after the close of the stock market. The Company will host a conference call and webcast at 4:30 P.M. ET, during which management will discuss the Company’s financial results and provide a general business overview and outlook. To listen to the live webcast and view the presentation slides, please visit the Investor Relations page of the Cerus website at http://ir.cerus.com. Participants may register for the call here. While not required, interested participants are encouraged to join 10 minutes prior to the start of the event. A replay will be avai
- SECCerus Corporation filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits8-K - CERUS CORP (0001020214) (Filer)
- INSIDERChief Financial Officer Green Kevin Dennis sold $99,105 worth of shares (33,676 units at $2.94) as part of a pre-agreed trading plan and gave a grant of 63,600 shares, decreasing direct ownership by 8% to 1,062,188 units (SEC Form 4) to cover withholding tax4 - CERUS CORP (0001020214) (Issuer)
- INSIDERChief Operating Officer Jayaraman Vivek K was granted 554,529 shares, gave a grant of 80,000 shares and sold $124,658 worth of shares (42,359 units at $2.94) as part of a pre-agreed trading plan, increasing direct ownership by 24% to 2,248,877 units (SEC Form 4) to satisfy withholding obligation4 - CERUS CORP (0001020214) (Issuer)
- INSIDERChief Legal Officer Jensen Chrystal gave a grant of 55,000 shares and sold $71,598 worth of shares (24,329 units at $2.94) as part of a pre-agreed trading plan, decreasing direct ownership by 8% to 966,657 units (SEC Form 4) (for withholding tax)4 - CERUS CORP (0001020214) (Issuer)
- INSIDERPresident and CEO Greenman William Mariner gave a grant of 192,500 shares and sold $299,937 worth of shares (101,919 units at $2.94) as part of a pre-agreed trading plan, decreasing direct ownership by 6% to 5,053,036 units (SEC Form 4) to cover taxes4 - CERUS CORP (0001020214) (Issuer)
- PRCerus to Showcase New Evidence, Innovation and Global Experience with the INTERCEPT Blood System at the 39th International ISBT CongressCerus Corporation (NASDAQ:CERS) announced today a company-sponsored lunch symposium and a selection of abstracts at the International Society of Blood Transfusion (ISBT) 39th International ISBT Congress, taking place in Kuala Lumpur, Malaysia, from June 20 through June 24, 2026. Transfusion medicine experts and professionals from around the world are expected to attend the ISBT Congress. "We look forward to highlighting how blood centers around the world are leveraging INTERCEPT technology to strengthen blood safety, improve operational efficiency and enhance patient care," said Christian Boutemy, vice president, international commercial operations at Cerus. "This year's abstracts reflect
- INSIDERDirector Bjerkholt Eric sold $53,180 worth of shares (20,454 units at $2.60), decreasing direct ownership by 7% to 261,679 units (SEC Form 4)4 - CERUS CORP (0001020214) (Issuer)
- SECCerus Corporation filed SEC Form 8-K: Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Creation of a Direct Financial Obligation8-K - CERUS CORP (0001020214) (Filer)
- PRCerus Corporation Closes New Debt Facility of Up to $110 MillionRefinancing extends maturity and lowers cost of capital Enhances financial flexibility and positions Cerus to drive sustainable growth Anticipated annual cash interest expense savings of up to $3.5 million Cerus Corporation (NASDAQ:CERS) announced today the closing of a new debt facility with MidCap Financial (MidCap), providing up to $110 million. The facility consists of a 5-year term loan and an asset-backed revolving loan. The refinancing is expected to reduce annual cash interest expense by up to $3.5 million, reflecting lower borrowing costs and an approximately $30 million reduction in outstanding term loan balance. Initial proceeds from the loan, together with cash on hand,
CERS FAQ
11 questionsWhat does Cerus Corporation do?
Cerus Corporation, a biomedical products company, focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company offers INTERCEPT Blood Systems for platelets and plasma, which is designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red...What is the latest news on CERS?
In the last 30 days Quantisnow tracked 8 wire items for CERS: 3 earnings updates, 3 SEC filings, 1 press release or news item and 1 13D/G filing. The most recent was published on November 13, 2026.What is CERS revenue?
Cerus Corporation (CERS) reported $254.23M of revenue for the twelve months ended Sep 30, 2026. Revenue for fiscal 2025 was $233.80M.Is CERS profitable?
No. Cerus Corporation reported a net loss of $7.36M for the twelve months ended Sep 30, 2026.How much cash and debt does CERS have?
Cerus Corporation reported $16.35M in cash and cash equivalents on its most recent balance sheet in SEC filings.Where does CERS stock trade?
Cerus Corporation (CERS) is listed on NASDAQ.What sector and industry is CERS in?
Cerus Corporation operates in the Health Care sector, Medical/Dental Instruments industry.When did Cerus Corporation go public?
Cerus Corporation (CERS) completed its IPO in 1997.What are analysts saying about CERS?
Across the last 4 analyst actions on Cerus Corporation, there was 1 upgrade and 2 downgrades. The most recent action was from BTIG Research: Buy with a $4.00 price target on 2026-05-01. Recent price targets range from $3.75 to $5.00.What companies are similar to CERS?
Notable peers in the same industry include MMM (3M Company), DXCM (DexCom Inc.), SYK (Stryker Corporation), BDX (Becton Dickinson and Company), MDLN (Medline Inc.). Compare CERS side-by-side with any of them on Quantisnow.How can I track CERS on Quantisnow?
Quantisnow aggregates Cerus Corporation's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow CERS to receive live email and push alerts on every new disclosure.